A Study to Evaluate the Safety and Effect of Treatment With Experimental Antiviral Drugs in Combination With Peginterferon Alpha-2a and Ribavirin in People With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie/Abbott Combination Study
A Study to Evaluate the Safety and Effect of Treatment With Experimental Antiviral Drugs in Combination With Peginterferon Alpha-2a and Ribavirin in People With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie/Abbott Combination Study
A study to evaluate the safety and effect of treatment with experimental antiviral drugs in
 combination with peginterferon alpha-2a and ribavirin in people with hepatitis C virus who
 did not respond to treatment in a previous AbbVie/Abbott combination study.
Inclusion Criteria:

 Main Inclusion: To be enrolled in this protocol, subjects must meet all of the following
 inclusion criteria:

 -  Subject must have experienced virologic failure as defined in a previous AbbVie/Abbott
 direct-acting antiviral (DAA) combination trial.

 -  Female subjects of childbearing potential must be willing to use two effective forms
 of birth control (not including oral contraceptives or contraceptives containing
 ethinyl estradiol) while receiving study drug and for 7 months (or per local ribavirin
 label) after stopping study drug.

 -  Males must be surgically sterile or have male partners only or agree to practice two
 effective forms of birth control throughout the course of the study, starting with
 Study Day 1 and for 7 months (or per local ribavirin label) after the last dose of
 study drug, unless abstinent from sexual intercourse.

 -  Subject must be considered an appropriate candidate for peginterferon (pegIFN)
 alpha-2a, ribavirin (RBV), ABT-450/ritonavir (r) and ABT-267 therapy in the opinion of
 the investigator.

 -  Subject is infected with hepatitis C virus (HCV) genotype 1 at screening.

 Subjects diagnosed with cirrhosis must also meet the following criteria:

 -  Compensated cirrhosis defined as Child-Pugh score of ≤ 6 at Screening.

 -  Absence of hepatocellular carcinoma based on a negative ultrasound, computed
 tomography (CT) scan or magnetic resonance imaging (MRI) performed within 3 months
 prior to Screening or during the Screening period.

 Exclusion Criteria:

 -  In subjects with a prior null or partial response to pegIFN/RBV treatment at any time
 prior to pre-screening for this study or any prior failure with pegIFN/RBV plus
 telaprevir, the presence of variants relative to the appropriate prototypic reference
 sequence (H77 for 1a or Con1 for 1b) at any of the following positions: NS3 155, 156,
 or 168; or NS5A 28, 29, 30, 31, 32, 58, or 93.

 -  Females who are pregnant or plan to become pregnant, or breast-feeding, or males whose
 partners are pregnant or planning to become pregnant within 7 months (or per local RBV
 label) after their last dose of RBV.

 -  Use of known strong inducers (e.g., phenobarbital, rifampin, carbamazepine, St. John's
 Wort) of Cytochrome P450 3A (CYP3A) within 2 weeks prior to study drug administration.

 -  Use of any medications contraindicated for use with pegIFN alpha-2a, RBV or ritonavir
 within 2 weeks prior to study drug administration. Prior to entering the study,
 subjects must be able to safely discontinue the contraindicated medication or switch
 to an acceptable alternative under supervision of the investigator.

 -  Discontinuation of antiviral therapy due to intolerance or a DAA- or RBV-associated
 adverse event in a previous AbbVie/Abbott DAA combination study.

 Subjects with compensated cirrhosis must also not meet the following criteria:

 -  Any current or past clinical evidence of Child-Pugh B or C Classification or clinical
 history of liver decompensation such as ascites (noted on physical exam), variceal
 bleeding or hepatic encephalopathy.

 -  Serum Alpha-Fetoprotein (sAFP) > 100 ng/mL at Screening.

 -  A screening ultrasound suspicious for hepatocellular carcinoma and confirmed with a
 subsequent CT scan or MRI during the screening period.